News for Akers Biosciences, Inc. (AKER)

Advancements and Projections in the Global Cholesterol Testing Market: Insights, Trends, Opportunities, and Recent Developments...

Breathalyzer technology for rapid and accurate alcohol level testing during sobriety checks, ensuring road safety and preventing drunk driving incidents....

SkyQuest projects that the breath analyzer market will attain a USD 8.12 billion value by 2030, with a CAGR of 15.91% over the forecast period (2023-2030)....

/PRNewswire/ -- The "Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles - Forecast to 2025" report...

Chicago, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Breath Analyzer Market size is expected to reach USD 1,167 million by 2025 from USD 524 million in 2020, at a...

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge...

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity...

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession...

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession...

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto.

(RTTNews) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio'...

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: RigNet, Inc. (NASDAQ: RNET) concerning...